Drugs / CENACITINIB
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05715125 | Jan 2023 → Jan 2024 | psoriatic arthritis | Ventyx Biosciences, Inc | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT05688852 | Jan 2023 → Jun 2024 | Crohn disease | Ventyx Biosciences, Inc | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT05655299 | Nov 2022 → Sep 2023 | psoriasis | Ventyx Biosciences, Inc | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CENACITINIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068046 ↗ |
| Known as | VTX958 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05688852 ↗ |
| Modality | Small molecule | — CHEMBL6068046 ↗ |